[{"id":"593b542b-470d-465e-ae6a-8f9b079a6849","acronym":"ALLIANCE-ABTC-1604","url":"https://clinicaltrials.gov/study/NCT03107780","created_at":"2021-01-18T15:18:36.892Z","updated_at":"2025-02-25T13:48:22.462Z","phase":"Phase 1","brief_title":"Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer","source_id_and_acronym":"NCT03107780 - ALLIANCE-ABTC-1604","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • MGMT","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navtemadlin (KRT-232)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/09/2018","start_date":" 07/09/2018","primary_txt":" Primary completion: 03/21/2019","primary_completion_date":" 03/21/2019","study_txt":" Completion: 02/07/2026","study_completion_date":" 02/07/2026","last_update_posted":"2025-02-21"},{"id":"5b783b7c-5a42-40ed-b63a-61150837a02a","acronym":"A021804","url":"https://clinicaltrials.gov/study/NCT04394858","created_at":"2021-01-29T07:20:43.079Z","updated_at":"2025-02-25T13:53:17.999Z","phase":"Phase 2","brief_title":"Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer","source_id_and_acronym":"NCT04394858 - A021804","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MGMT • CD4","pipe":"","alterations":" ","tags":["MGMT • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-20"},{"id":"3c5d0961-29c6-44c5-9f18-012dc3b4ae3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06504381","created_at":"2025-02-25T14:04:35.935Z","updated_at":"2025-02-25T14:04:35.935Z","phase":"Phase 1/2","brief_title":"DB107-RRV, DB107-FC, and Radiation Therapy with or Without Temozolomide (TMZ) for High Grade Glioma","source_id_and_acronym":"NCT06504381","lead_sponsor":"University of California, San Francisco","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • vocimagene amiretrorepvec/extended release flucytosine (DB107)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 01/08/2025","start_date":" 01/08/2025","primary_txt":" Primary completion: 01/31/2028","primary_completion_date":" 01/31/2028","study_txt":" Completion: 01/31/2042","study_completion_date":" 01/31/2042","last_update_posted":"2025-02-19"},{"id":"22e86fd8-4f8f-4456-992c-88f257edf9a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05345002","created_at":"2022-04-25T21:58:14.873Z","updated_at":"2025-02-25T14:41:19.773Z","phase":"Phase 2","brief_title":"All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma","source_id_and_acronym":"NCT05345002","lead_sponsor":"Stephen Bagley, MD, MSCE","biomarkers":" IDH1 • IDH2 • MGMT","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-14"},{"id":"451a8a7f-851d-493a-9270-889080e917a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05086497","created_at":"2021-10-21T13:53:08.372Z","updated_at":"2025-02-25T15:19:19.323Z","phase":"","brief_title":"WBSI Guided Personalized Delivery of TTFields","source_id_and_acronym":"NCT05086497","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH wild-type"],"overall_status":"Recruiting","enrollment":" Enrollment 155","initiation":"Initiation: 01/15/2023","start_date":" 01/15/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-11"},{"id":"29c36fa3-ec25-4585-bc53-d76f48cbd87a","acronym":"GIANT","url":"https://clinicaltrials.gov/study/NCT06816927","created_at":"2025-02-25T15:46:23.088Z","updated_at":"2025-02-25T15:46:23.088Z","phase":"Phase 2","brief_title":"Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab","source_id_and_acronym":"NCT06816927 - GIANT","lead_sponsor":"Duke University","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • relatlimab (BMS-986016)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/01/2029","primary_completion_date":" 06/01/2029","study_txt":" Completion: 06/01/2031","study_completion_date":" 06/01/2031","last_update_posted":"2025-02-10"},{"id":"b172bb8d-07dd-4d40-b459-cb7946457b73","acronym":"NRG-BN007","url":"https://clinicaltrials.gov/study/NCT04396860","created_at":"2021-01-18T21:13:04.295Z","updated_at":"2025-02-25T15:34:40.901Z","phase":"Phase 2/3","brief_title":"Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma","source_id_and_acronym":"NCT04396860 - NRG-BN007","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • TMB • IDH1 • MGMT","pipe":" | ","alterations":" PD-L1 expression • MGMT promoter methylation • IDH1 R132","tags":["PD-L1 • TMB • IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MGMT promoter methylation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 04/13/2023","primary_completion_date":" 04/13/2023","study_txt":" Completion: 03/11/2025","study_completion_date":" 03/11/2025","last_update_posted":"2025-02-10"},{"id":"0af43381-6afd-4912-9b0c-5801c2007fc0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05432804","created_at":"2022-06-27T14:54:16.638Z","updated_at":"2025-02-25T16:46:08.151Z","phase":"Phase 1/2","brief_title":"Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment","source_id_and_acronym":"NCT05432804","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 03/20/2023","start_date":" 03/20/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-06"},{"id":"0761f5fc-4fb6-468e-bb3d-390adb9bdabf","acronym":"","url":"https://clinicaltrials.gov/study/NCT06113705","created_at":"2023-11-02T15:12:45.694Z","updated_at":"2025-02-25T17:26:31.436Z","phase":"","brief_title":"Imaging and Biological Markers for Prediction and Identification of Glioblastoma Pseudoprogression: a Prospective Study.","source_id_and_acronym":"NCT06113705","lead_sponsor":"Istituto Clinico Humanitas","biomarkers":" IDH1 • IDH2 • MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["IDH1 • IDH2 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-01-31"},{"id":"6df094c2-9111-440a-b8d9-ef9270259908","acronym":"","url":"https://clinicaltrials.gov/study/NCT03961971","created_at":"2021-07-05T17:22:45.637Z","updated_at":"2025-02-25T15:43:33.280Z","phase":"Phase 1","brief_title":"Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM","source_id_and_acronym":"NCT03961971","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • sabatolimab (MBG453)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 02/18/2020","start_date":" 02/18/2020","primary_txt":" Primary completion: 11/16/2022","primary_completion_date":" 11/16/2022","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-01-03"},{"id":"b0a219e9-f08b-4dc8-9baf-aea7746f89fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02287428","created_at":"2021-01-18T10:46:55.814Z","updated_at":"2025-02-25T16:14:11.420Z","phase":"Phase 1","brief_title":"Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM","source_id_and_acronym":"NCT02287428","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • temozolomide • Hiltonol (poly-ICLC) • Neo Vax (NEO-PV-01)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-12-05"},{"id":"8c4a219e-7193-412f-88db-6bed71bfbf96","acronym":"","url":"https://clinicaltrials.gov/study/NCT01985087","created_at":"2025-09-06T14:28:38.946Z","updated_at":"2025-09-06T14:28:38.946Z","phase":"Phase 1/2","brief_title":"A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70","source_id_and_acronym":"NCT01985087","lead_sponsor":"University of Louisville","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/01/2014","start_date":" 09/01/2014","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-10-31"},{"id":"2e2ffa16-9364-47ec-af17-c174c6bba967","acronym":"ARISTOCRAT","url":"https://clinicaltrials.gov/study/NCT05629702","created_at":"2022-11-29T14:57:14.668Z","updated_at":"2024-07-02T16:34:25.626Z","phase":"Phase 2","brief_title":"ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids","source_id_and_acronym":"NCT05629702 - ARISTOCRAT","lead_sponsor":"University of Birmingham","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Sativex (nabiximols)"],"overall_status":"Recruiting","enrollment":" Enrollment 234","initiation":"Initiation: 02/03/2023","start_date":" 02/03/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-06-17"},{"id":"eb5c9ee3-620e-48d0-bab8-f8f2914ede1d","acronym":"NRG-BN010","url":"https://clinicaltrials.gov/study/NCT04729959","created_at":"2021-03-09T19:55:01.650Z","updated_at":"2024-07-02T16:34:27.180Z","phase":"Phase 2","brief_title":"Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma","source_id_and_acronym":"NCT04729959 - NRG-BN010","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["EGFR • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Actemra IV (tocilizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 03/11/2022","start_date":" 03/11/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-11"},{"id":"3c4b70e5-0095-4941-b867-c448ada0131d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05879250","created_at":"2023-05-30T14:05:05.692Z","updated_at":"2024-07-02T16:34:59.705Z","phase":"Phase 2","brief_title":"WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma","source_id_and_acronym":"NCT05879250","lead_sponsor":"Northwestern University","biomarkers":" IDH1 • MGMT","pipe":" | ","alterations":" RAS wild-type • IDH wild-type","tags":["IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WP1066"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 05/22/2024","start_date":" 05/22/2024","primary_txt":" Primary completion: 12/27/2027","primary_completion_date":" 12/27/2027","study_txt":" Completion: 12/27/2028","study_completion_date":" 12/27/2028","last_update_posted":"2024-05-31"},{"id":"a6d31f53-b654-4da8-90c1-1275e4f0fcec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04485949","created_at":"2024-03-05T19:33:23.646Z","updated_at":"2024-07-02T16:34:59.826Z","phase":"Phase 2","brief_title":"A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma","source_id_and_acronym":"NCT04485949","lead_sponsor":"Imvax","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • IGV-001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 03/20/2023","start_date":" 03/20/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-05-31"},{"id":"caca578c-aaca-49e5-a97d-ca67554ac90d","acronym":"CLINGLIO","url":"https://clinicaltrials.gov/study/NCT04250922","created_at":"2021-01-18T20:39:26.321Z","updated_at":"2024-07-02T16:34:59.713Z","phase":"Phase 2/3","brief_title":"LAM561 With RT and TMZ for Adults With Glioblastoma","source_id_and_acronym":"NCT04250922 - CLINGLIO","lead_sponsor":"Laminar Pharmaceuticals","biomarkers":" IDH1 • MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH wild-type","tags":["IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Minerval (idroxioleic acid)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 10/15/2024","primary_completion_date":" 10/15/2024","study_txt":" Completion: 05/30/2025","study_completion_date":" 05/30/2025","last_update_posted":"2024-05-31"},{"id":"b56f4287-89ee-4b31-a0fe-61bc9ba09fe4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05986851","created_at":"2023-08-14T15:10:00.555Z","updated_at":"2024-07-02T16:35:00.485Z","phase":"Phase 2","brief_title":"Azeliragon in MGMT Unmethylated Glioblastoma","source_id_and_acronym":"NCT05986851","lead_sponsor":"Cantex Pharmaceuticals","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azeliragon (TTP488)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/12/2023","start_date":" 09/12/2023","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-29"},{"id":"ea0612d8-6aff-4c58-8397-63f6b6a41420","acronym":"CheckMate 548","url":"https://clinicaltrials.gov/study/NCT02667587","created_at":"2021-07-10T10:53:19.002Z","updated_at":"2024-07-02T16:35:00.332Z","phase":"Phase 3","brief_title":"An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)","source_id_and_acronym":"NCT02667587 - CheckMate 548","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • temozolomide"],"overall_status":"Completed","enrollment":" Enrollment 716","initiation":"Initiation: 05/09/2016","start_date":" 05/09/2016","primary_txt":" Primary completion: 12/22/2020","primary_completion_date":" 12/22/2020","study_txt":" Completion: 04/09/2024","study_completion_date":" 04/09/2024","last_update_posted":"2024-05-29"},{"id":"9a4116e1-774f-46ea-a206-c1400d303037","acronym":"A071102","url":"https://clinicaltrials.gov/study/NCT02152982","created_at":"2021-07-10T10:52:52.085Z","updated_at":"2024-07-02T16:35:02.746Z","phase":"Phase 2/3","brief_title":"Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","source_id_and_acronym":"NCT02152982 - A071102","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • veliparib (ABT-888)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 447","initiation":"Initiation: 12/15/2014","start_date":" 12/15/2014","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-05-17"},{"id":"12ef23c8-0f04-4348-90aa-89217bc8e0c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04555577","created_at":"2021-07-05T17:32:33.242Z","updated_at":"2024-07-02T16:35:03.500Z","phase":"Phase 1","brief_title":"Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma","source_id_and_acronym":"NCT04555577","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • peposertib (M3814)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 09/20/2020","start_date":" 09/20/2020","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2024-05-15"},{"id":"77eb3cd1-2540-4b18-b06d-2e8b7aee2b46","acronym":"NCI-2018-00872","url":"https://clinicaltrials.gov/study/NCT03452930","created_at":"2021-07-05T17:12:08.426Z","updated_at":"2024-07-02T16:35:03.679Z","phase":"Phase 1","brief_title":"Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma","source_id_and_acronym":"NCT03452930 - NCI-2018-00872","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tinostamustine (EDO-S101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-05-15"},{"id":"3b885732-0c6b-4c16-beb1-fbc5553cef67","acronym":"GlioVax","url":"https://clinicaltrials.gov/study/NCT03395587","created_at":"2021-01-18T16:45:21.670Z","updated_at":"2024-07-02T16:35:04.022Z","phase":"Phase 2","brief_title":"Efficiency of Vaccination With Lysate-loaded Dendritic Cells in Patients With Newly Diagnosed Glioblastoma","source_id_and_acronym":"NCT03395587 - GlioVax","lead_sponsor":"Heinrich-Heine University, Duesseldorf","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 03/06/2018","start_date":" 03/06/2018","primary_txt":" Primary completion: 11/06/2026","primary_completion_date":" 11/06/2026","study_txt":" Completion: 03/06/2027","study_completion_date":" 03/06/2027","last_update_posted":"2024-05-14"},{"id":"a51211da-d984-44fa-b40a-53dd5c9345df","acronym":"GLUGLIO","url":"https://clinicaltrials.gov/study/NCT05664464","created_at":"2024-05-11T04:13:20.132Z","updated_at":"2024-07-02T16:35:04.444Z","phase":"Phase 1/2","brief_title":"Glutamate Inhibitors in Glioblastoma","source_id_and_acronym":"NCT05664464 - GLUGLIO","lead_sponsor":"University of Zurich","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-10"}]